Table I.

Enhanced vaccinia virus replication in the absence of γδ T cells

Expt.StrainaDays PIVirusVirus Titer (mean log10 PFU/organ ± SEM)b
SpleenFat padsLiver
1C57BL/6Day 3VV4.7 ± 0.2*c4.8 ± 0.24.6 ± 0.1
δTCR KO5.1 ± 0.15.3 ± 0.015.1 ± 0.1
2C57BL/6Day 4VV3.9 ± 0.33.9 ± 0.33.3 ± 0.6
δ TCR KO4.9 ± 0.35.8 ± 0.14.6 ± 0.2
3C57BL/6Day 5VV<2.0 ± 0.02.9 ± 0.4<2.0 ± 0.0§
δ TCR KO2.7 ± 0.34.2 ± 0.42.9 ± 0.5
4δ TCR+/− (129× B6)Day 3VV3.9 ± 0.34.4 ± 0.15NDd
δ TCR−/− (129× B6)4.9 ± 0.26.2 ± 0.31ND
5C57BL/6+ control IgGDay 4VV<2.0 ± 0.33.5 ± 0.6<2.3 ± 0.2
C57BL/6+ anti-δ3.4 ± 0.44.5 ± 0.43.1 ± 0.3
6β TCR KODay 4VV<1.3 ± 0.24.6 ± 0.2<2.2 ± 0.2
β+ δ TCR KO3.1 ± 0.35.0 ± 0.13.1 ± 0.3
7β TCR KODay 8VV<1.2 ± 0.2ND<2.0 ± 0
β+ δ TCR KO2.6 ± 0.8ND4.2 ± 0.4
8C57BL/6Day 4LCMV5.6 ± 0.1NDND
δ TCR KO5.4 ± 0.3NDND
  • a Four to six mice used per group. δ TCR KO mice are on a C57BL/6 background except in Expt. 4, where they are on a 129 × C57BL/6 background. The +/− (129 × C57BL/6) mice are heterozygous for the δ TCR KO.

  • b VV and LCMV were titrated on vero cell monolayers using a 3-day and 5-day plaque assay, respectively.

  • c Statistically significant difference between C57BL/6 and δ TCR KO mice (Student’s t test). *, p = 0.09; †, p < 0.05; ‡, p = 0.055; §, p = 0.07. Each experiment is representative of two or three similar experiments.

  • d ND, Not done.